Is PMCB or PTHS more undervalued in 2026?

CirclFi compares PharmaCyte Biotech, Inc. (PMCB) and Pelthos Therapeutics Inc. (PTHS) using 13 institutional-grade valuation models. PMCB has a Quality of Company score of 5.1/10 while PTHS scores 4.4/10.

Which is a better buy — PMCB or PTHS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PMCB and PTHS valuations compare?

PMCB at $0.83 and PTHS at $26.47 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PMCB vs PTHS Valuation Comparison 2026 — Intrinsic Value Analysis

PMCB

Biological Products, (No Diagnostic Substances)

PharmaCyte Biotech, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$0.83

Last close

Models

3/13

Active

PTHS

Biological Products, (No Diagnostic Substances)

Pelthos Therapeutics Inc.

Quality

4.4

out of 10

Value Trap

LOW

Price

$26.47

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	PMCB Fair Value	PMCB Upside	PTHS Fair Value	PTHS Upside
Bayesian DCF	Intrinsic	—	—	$9.93	-62.5%
Earnings Power Value	Intrinsic	—	—	$16.77	-32.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.46	+194.8%	—	—
PWERM	Option-Based	$2.23	+167.6%	$51.83	+95.8%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PMCB vs PTHS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PMCB vs PTHS — Which Stock Is More Undervalued?

PMCB scores higher with a 5.1/10 quality rating vs PTHS's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing PharmaCyte Biotech, Inc. (PMCB) and Pelthos Therapeutics Inc. (PTHS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PMCB currently trades at $0.83 with a QOC of 5.1/10, while PTHS trades at $26.47 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).